Cell and gene therapies will unquestionably
comprise a large part of biotech companies’
portfolios in the coming decades.
Unlike traditional large molecules, these
products have different manufacturing
and supply chain needs, requiring a fresh
look at existing regulations. Yet these challenges
will need to be addressed due to the
promise of these products to cure a variety
of diseases and disorders.